Zydus & TLC sign agreement to market critical drug to treat Black Fungus

by IANS |

New Delhi, May 26 (IANS) Zydus and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.

AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.

The Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of TLC for Amphotericin B Liposome for Injection 50mg or AmphoTLC for immediate importation as per approved usage and indication.

AmphoTLC is the first and only complex generic drug to have achieved bioequivalence to Gilead's AmBisome, proving its sameness to the safest form of amphotericin B in the world. With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage.

Mucormycosis is a serious fungal infection also known as black fungus, and COVID Associated Mucormycosis is a life-threatening form of mucormycosis which has emerged as a post-COVID complication, infecting about 30% of COVID patients who are diabetic or otherwise immunocompromised. If progression of the infection is not treated early, over 60% of patients could die. The increasing number of CAM cases has resulted in unprecedented demand for liposomal amphotericin B, the key drug to treat mucormycosis, causing an acute shortage of the drug.

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. The drug is approved in Taiwan and has been manufactured and sold by Yung Shin Pharmaceutical Industrial Co. (YSP) for several years. The approval of AmphoTLC in India follows the conduct of comprehensive due diligence by regulators in India based on the numerous years of development TLC has dedicated as well as its quality performance in the developed markets. The steep increase in price and the financial burden it brings is forcing patients to opt for conventional amphotericin B, which is known for its nephrotoxicity, with many patients having to discontinue usage due to renal toxicities.

Speaking on the development, Sharvil Patel, Managing Director, of Cadila Healthcare Ltd, said, "With India facing an acute shortage of the drug to treat mucormycosis, we are making this critical drug available in India on an immediate basis. The need of the hour is to tackle this life-threatening infection with a safe and effective therapy."

Commenting on the speed of the process, George Yeh, President of TLC, said, "We would like to thank Zydus for their quick action and cooperation in enabling a swift commercialization process. TLC is glad to be able to assist in the humanitarian crisis in such a quick fashion, and as our corporate tagline – Delivering Hope for Life – depicts, we will be delivering the first batch of AmphoTLC to India to help assuage the urgent need for one of the safest and most effective antifungal drugs very soon."

Latest News
IPL 2024: 'Sai Kishore did not expect I will go after him off the first ball', says CSK's Shivam Dube Fri, Mar 29, 2024, 03:55 PM
Talks with Ukrainian FM focused on conflict with Russia, says EAM Jaishankar Fri, Mar 29, 2024, 03:49 PM
Started my career on shop floor of auto plant: Anand Mahindra to Elon Musk Fri, Mar 29, 2024, 03:42 PM
Chinese military offers help to Pakistan to curb terrorism Fri, Mar 29, 2024, 03:39 PM
Kangana Ranaut holds roadshow in Mandi, responds to Supriya Shrinate's 'bhao' jibe Fri, Mar 29, 2024, 03:36 PM
CPI tries to revive itself by launching ex-IPS officer in UP's Faizabad Fri, Mar 29, 2024, 03:29 PM
Mandya in Karnataka to witness mega clash between Kumaraswamy and Star Chandru Fri, Mar 29, 2024, 03:26 PM
I-T seizes unaccounted cash from Kolkata bizman's office Fri, Mar 29, 2024, 03:24 PM
Byju's EGM on rights issue ends sans objections, dissenting investors skip meet Fri, Mar 29, 2024, 03:12 PM
Anti-abuse provisions should not be used in receipt of capital from credible investors: Experts Fri, Mar 29, 2024, 03:09 PM
UP: Kamaal R Khan's brother to contest from Saharanpur on BSP ticket Fri, Mar 29, 2024, 02:59 PM
Pakistan: Alarm bells ring as judicial bodies gear up to protect their judges against 'targeted assault' Fri, Mar 29, 2024, 02:50 PM
Judicial probe ordered in Mukhtar Ansari's death Fri, Mar 29, 2024, 02:46 PM
Stories come knocking, characters start whispering to me: Filmmaker Rima Das Fri, Mar 29, 2024, 02:45 PM
Magisterial probe ordered into Mukhtar Ansari's death Fri, Mar 29, 2024, 12:52 PM